

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM320324

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Osiris Therapeutics, Inc.		09/22/2014	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Mesoblast International Sarl		
Street Address:	Route de Pres-Bois 20		
City:	Meyrin		
State/Country:	SWITZERLAND		
Postal Code:	1217		
Entity Type:	CORPORATION: SWITZERLAND		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	3620975	PROCHYMAL	
Registration Number:	4529732	CHONDROGEN	
CORRESPONDENCE DATA			
Fax Number:	3127758100		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3127758000		
Email:	trademarks@mcandrews-ip.com		
Correspondent Name:	Priscilla F. Gallagher		
Address Line 1:	500 W Madison St		
Address Line 2:	34th Fl		
Address Line 4:	Chicago, ILLINOIS 60661		
ATTORNEY DOCKET NUMBER:	34240US01; 34249US02		
DOMESTIC REPRESENTATIVE			
Name:	Priscilla F. Gallagher		
Address Line 1:	500 W Madison St		
Address Line 2:	34th Fl		
Address Line 4:	Chicago, ILLINOIS 60661		
NAME OF SUBMITTER:	Priscilla F. Gallagher		
SIGNATURE:	/pfg/		

OP \$65.00 3620975

DATE SIGNED:	10/16/2014
Total Attachments: 2 source=OSIR-USA Trademark Assignment-22Sep2014#page1.tif source=OSIR-USA Trademark Assignment-22Sep2014#page2.tif	

TRADEMARK ASSIGNMENT

This Assignment is by and between Osiris Therapeutics, Inc., a Delaware corporation having a principal place of business at 7015 Albert Einstein Avenue, Columbia, Maryland 21046 ("Assignor") and Mesoblast International Sàrl, a company organized under the laws of Switzerland whose address is Route de Pre-Bois 20, 1217 Meyrin, Switzerland ("Assignee");

WHEREAS, Assignor and Assignee are parties to an Asset Purchase Agreement, and an Intellectual Property Assignment dated October 10, 2013 (the "Assignment"), pursuant to which Assignor agreed to sell and assign the Assigned IPR (as defined in the Assignment) to Assignee;

WHEREAS Assignor is the owner of the entire right, title and interest in and to the trademarks identified in Schedule 1.1-G of the Assignment, including U.S. Trademark Registration No. 3,620,975 for the trademark PROCHYMAL, together with the goodwill of the business associated therewith; and U.S. Trademark Application No. 77/617,756 for the trademark CHONDROGEN filed as an intent to use application under Section (b)(1) of 15 U.S.C. §1051;


WHEREAS Assignee is the successor to Assignor's business to which the CHONDROGEN trademark pertains;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are acknowledged, Assignor does assign and transfer unto Assignee its entire right, title and interest in and to the trademarks PROCHYMAL and CHONDROGEN, including U.S. Trademark Registration No. 3,620,975, and U.S.

Trademark Application No. 77/617,756 (now Registration No. 4,529,732), together with the goodwill of the business in connection with which said trademarks are used.

IN WITNESS whereof, this instrument has been duly executed by Osiris Therapeutics, Inc., this 22nd day of September, 2014.

OSIRIS THERAPEUTICS, INC.

Signature:  _____

Printed Name: Philip R. Jacoby, Jr.

Title: Chief Financial Officer & Corporate Secretary